Spectrum Pharmaceuticals Inc (SPPI)

6.42
0.00 (0.00)
NASDAQ : Health Care
Prev Close 6.42
Open 6.42
Day Low/High 6.34 / 6.49
52 Wk Low/High 4.14 / 7.74
Volume 593.01K
Avg Volume 710.90K
Exchange NASDAQ
Shares Outstanding 80.25M
Market Cap 522.44M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Spectrum Pharmaceuticals Reports Fourth Quarter 2016 And Full Year 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2016 And Full Year 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

First Week of SPPI April 21st Options Trading

First Week of SPPI April 21st Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new April 21st contracts and identified the following call contract of particular interest.

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 RBC Capital Markets Global Healthcare Conference On February 23rd

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 RBC Capital Markets Global Healthcare Conference On February 23rd

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options

Commit To Purchase Spectrum Pharmaceuticals At $3, Earn 16.6% Annualized Using Options

Investors eyeing a purchase of Spectrum Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $3 strike, which has a bid at the time of this writing of 20 cents.

Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer

Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib In Lung Cancer At The 17th IASLC World Conference On Lung Cancer

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the oral presentation of data...

Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals Highlights Survival Advantage In A Case Match Control Analysis Of The PROPEL Study With FOLOTYN® (pralatrexate Injection) at The 58th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the presentation of data from a...

Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016

Spectrum Pharmaceuticals Highlights Five Abstracts On ROLONTIS™ (eflapegrastim) And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS) In San Antonio, Texas, December 6-10, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016

Spectrum Pharmaceuticals Highlights Four Abstracts At The 58th Annual Meeting Of The American Society Of Hematology (ASH) In San Diego, California, December 3-6, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.

Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  November 21, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

Spectrum Pharmaceuticals Announces Poziotinib Data Presentation At The 17th IASLC World Conference On Lung Cancer In Vienna, Austria, December 4-7, 2016

Spectrum Pharmaceuticals Announces Poziotinib Data Presentation At The 17th IASLC World Conference On Lung Cancer In Vienna, Austria, December 4-7, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that scientists from MD...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Spectrum Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of November 21, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Spectrum Pharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of November 21, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc.

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Provides Third Quarter Financial Update

Spectrum Pharmaceuticals Provides Third Quarter Financial Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced today financial results for...

SPPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Shareholders Of A Class Action Involving Spectrum Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of November 21, 2016

SPPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Shareholders Of A Class Action Involving Spectrum Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of November 21, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Provides Third Quarter Financial And Pipeline Update

Spectrum Pharmaceuticals Provides Third Quarter Financial And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced that the earnings...

GPM Reminds Investors Of The November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The November 21st Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the November 21, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

Tax-Loss Selling Offers Stock-Picking Opportunities

Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.

Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

Cohen Milstein Sellers & Toll PLLC Announces Investigation Of Spectrum Pharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC Announces Investigation Of Spectrum Pharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Announces Appointment Of Luigi Lenaz, M.D., As Lead Director

Spectrum Pharmaceuticals Announces Appointment Of Luigi Lenaz, M.D., As Lead Director

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that independent director...

Spectrum Pharmaceuticals Becomes Oversold (SPPI)

Spectrum Pharmaceuticals Becomes Oversold (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

SPPI LOSS NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action Filed By Firm - SPPI

SPPI LOSS NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action Filed By Firm - SPPI

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Spectrum Pharmaceuticals, Inc.